Publicaciones en colaboración con investigadores/as de Hospital Universitario Puerta de Hierro (22)

2024

  1. Letter to the Editor: Serum Identification of At-Risk MASH: The Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF)

    Hepatology

  2. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  3. Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)

    Hepatology, Vol. 79, Núm. 1, pp. 135-148

  4. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

2023

  1. Estado actual y retos futuros de la medicina de laboratorio en España: un análisis de la Sociedad Española de Medicina de Laboratorio (SEQCML)

    Advances in Laboratory Medicine, Vol. 4, Núm. 1, pp. 81-91

  2. Screening uptake of colonoscopy versus fecal immunochemical testing in first-degree relatives of patients with non-syndromic colorectal cancer: A multicenter, open-label, parallel-group, randomized trial (ParCoFit study)

    PLoS Medicine, Vol. 20, Núm. 10

  3. State of affairs and future challenges in laboratory medicine in Spain: an analysis of the Spanish Society of Laboratory Medicine (SEQCML)

    Advances in Laboratory Medicine, Vol. 4, Núm. 1, pp. 70-80

2022

  1. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Cancers, Vol. 14, Núm. 20

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

  2. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

  3. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

    Blood, Vol. 138, Núm. 17, pp. 1583-1589

2020

  1. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5

  2. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

  3. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

  4. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25

  5. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596

2019

  1. Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

    Leukemia and Lymphoma, Vol. 60, Núm. 5, pp. 1146-1155

  2. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

    Therapeutic Advances in Gastroenterology, Vol. 12

2017

  1. Prevalence of malnutrition and nutritional characteristics of patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 11, Núm. 12, pp. 1430-1439

2010

  1. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma

    Genes Chromosomes and Cancer, Vol. 49, Núm. 5, pp. 439-451